Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHO-V08 in healthy adults
NCT07016152Phase 1Recruiting
- Sponsor
- CHO Pharma
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CHO-V08 in Klebsiella pneumoniae infection (2 cohorts), sponsored by CHO Pharma. Primary endpoint: Safety and Reactogenicity of CHO-V08 at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
CHO-V08
03
Conditions
Klebsiella pneumoniae infection
Beyond the preview
Go deeper on NCT07016152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016152.